Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances

Citius Oncology, Inc. (Nasdaq: CTOR) has appointed Jonathan Peri, Ph.D., J.D., as an independent director, expanding its board as the... Read More

The post Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances appeared first on citybiz.